Customer Education

Webinar: CRISPR Activator Libraries: Benefits of a whole genome gain-of-function screen

Webinar Title: CRISPR Activator Libraries: Benefits of a whole genome gain-of-function screen

Date: Tuesday, November 28, 2017

Time: 10:00 AM CST

Duration: 60 minutes

 What Does it Cover?

CRISPR-Cas9 nucleases have revolutionized genome editing enabling unprecedented efficiency of targeted mutagenesis. The ability to perform large-scale, whole genome loss-of-function screens has allowed for the rapid identification of gene pathways and targets relevant to drug resistance and disease. The CRISPR SAM activator libraries extend the reach of whole genome screening beyond simple knockout, delivering transcriptional co-regulators to a specific human or mouse target sequence using modified dCas9/gRNA complexes. In this webinar, we will introduce new strategies for forward genetic screening using CRISPR SAM activator libraries.  We will discuss the application of this technology as it pertains to experimental design, delivery mechanisms, data analysis, and target validation.

 What Will You Learn?

  • What CRISPRa is, how it works, and how it complements CRISPR-Cas9
  • How to design a whole genome library screen using CRISPRa
  • How to perform data analysis and target validation on a pooled screen


Speaker Bio
Andrew Ravanelli, Ph.D.
Senior R&D Scientist, Genome and Epigenome Editing
Andrew obtained his Ph.D. in Cell Biology from Duke University, where he dissected the in vivo molecular functions of a novel actin nucleator during ciliogenesis and embryonic development in mouse and zebrafish. He completed a postdoctoral fellow in Pedatrics at the University of Colorado School of Medicine where he used pharmacological and genetic manipulations coupled with 4D confocal imaging in zebrafish to investigate cell fate specification among neural stem and progenitor cells in the developing brain and spinal cord. Andrew joined MilliporeSigma in 2016 and has been developing novel mechanisms to modulate gene expression using CRISPR-Cas9.